Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $8.17.

Several equities research analysts have recently issued reports on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Chardan Capital lifted their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. Bank of America started coverage on shares of Taysha Gene Therapies in a research report on Friday, July 11th. They set a “buy” rating and a $8.00 price objective for the company. JMP Securities lifted their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning acquired 750,000 shares of the firm’s stock in a transaction on Friday, May 30th. The stock was bought at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider directly owned 2,841,704 shares of the company’s stock, valued at approximately $7,814,686. The trade was a 35.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.78% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently bought and sold shares of TSHA. Granahan Investment Management LLC raised its holdings in shares of Taysha Gene Therapies by 0.3% in the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock valued at $2,281,000 after buying an additional 4,412 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after buying an additional 8,076 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Taysha Gene Therapies by 43.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock valued at $55,000 after buying an additional 9,494 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock valued at $6,182,000 after buying an additional 9,591 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after buying an additional 11,390 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $2.54 on Monday. The company has a fifty day simple moving average of $2.56 and a two-hundred day simple moving average of $1.96. The company has a market cap of $545.24 million, a price-to-earnings ratio of -7.47 and a beta of 0.97. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.77. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $3.31.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $2.30 million during the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative return on equity of 104.93%. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. As a group, equities analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.